Advances in Alzheimer's Disease
Vol.2 No.3(2013), Paper ID 37276, 16
pages
DOI:10.4236/aad.2013.23012
Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial
Timothy Nicholas, Sridhar Duvvuri, Claire Leurent, David Raunig, Tracey Rapp, Phil Iredale, Carolyn Rowinski, Robert Carr, Patrick Roberts, Athan Spiros, Hugo Geerts
Pfizer Global Research and Development, Groton, USA
Pfizer Global Research and Development, Groton, USA
Pfizer Global Research and Development, Groton, USA
ICON, North Wales, USA
Pfizer Global Research and Development, Groton, USA
Pfizer Global Research and Development, Groton, USA
Pfizer Global Research and Development, Groton, USA
In Silico Biosciences, Lexington, USA
In Silico Biosciences, Lexington, USA
In Silico Biosciences, Lexington, USA
Copyright © 2013 Timothy Nicholas, Sridhar Duvvuri, Claire Leurent, David Raunig, Tracey Rapp, Phil Iredale, Carolyn Rowinski, Robert Carr, Patrick Roberts, Athan Spiros, Hugo Geerts et al. This is
an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
How to Cite this Article
Nicholas, T. , Duvvuri, S. , Leurent, C. , Raunig, D. , Rapp, T. , Iredale, P. , Rowinski, C. , Carr, R. , Roberts, P. , Spiros, A. and Geerts, H. (2013) Systems pharmacology modeling in neuroscience: Prediction and outcome of PF-04995274, a 5-HT4 partial agonist, in a clinical scopolamine impairment trial.
Advances in Alzheimer's Disease,
2, 83-98. doi:
10.4236/aad.2013.23012.